Expertise in
10
conditions

Dima Sharkawi-El

London, ENG, GB 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
10
conditions
London, ENG, GB 

Overview

Dima Sharkawi-El practices in London, United Kingdom. Ms. Sharkawi-El is highly rated in 10 conditions, according to our data. Her top areas of expertise are Prolymphocytic Leukemia, Anaplastic Large Cell Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 57 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender

Female

Locations

London, ENG, United Kingdom
Other Locations
Sutton Upon Derwent, ENG, United Kingdom
Mount Vernon Cancer Centre, Mount Vernon Hospital, Middlesex, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)
A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)
Enrollment Status: Recruiting
Publish Date: October 03, 2025
Intervention Type: Drug
Study Drugs: Selinexor, Rituximab, Gemcitabine, Dexamethasone, Cisplatin
Study Phase: Phase 2/Phase 3
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Pirtobrutinib, Idelalisib, Bendamustine, Rituximab
Study Phase: Phase 3
Phase I/II Study to Determine the Maximum Tolerated Dose and Activity of the Combination of Romidepsin and Carfilzomib in Relapsed or Refractory Peripheral T-cell Lymphoma
Phase I/II Study to Determine the Maximum Tolerated Dose and Activity of the Combination of Romidepsin and Carfilzomib in Relapsed or Refractory Peripheral T-cell Lymphoma
Enrollment Status: Completed
Publish Date: May 18, 2022
Intervention Type: Drug
Study Drugs: Romidepsin, Carfilzomib
Study Phase: Phase 1/Phase 2
View 2 Less Clinical Trial

57 Total Publications

Updated consensus guidelines for the diagnosis and management of patients with hairy cell leukemia (HCL) and HCL-variant.
Updated consensus guidelines for the diagnosis and management of patients with hairy cell leukemia (HCL) and HCL-variant.
Journal: Blood
Published: January 05, 2026

Frequently Asked Questions about Dima Sharkawi-El

Is Dima Sharkawi-El a top-rated expert for Prolymphocytic Leukemia?

MediFind is an objective health platform that identifies experts based on real-world data. Dima Sharkawi-El is classified as an Distinguished expert for Prolymphocytic Leukemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Dima Sharkawi-El participate in research or clinical trials?

Yes. Dima Sharkawi-El has published 57 articles and abstracts on conditions like Prolymphocytic Leukemia. You can view a list of Dima Sharkawi-El's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Sharkawi-El's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 13 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile